glp1versus

Foundayo vs Trulicity

orforglipron (GLP-1 receptor agonist (oral small-molecule)) vs dulaglutide (GLP-1 receptor agonist) — a complete side-by-side comparison.

Eli Lilly and CompanyEli Lilly

Foundayo weight loss

12.4%

Trulicity weight loss

3.1%

Foundayo dosing

Once daily

Trulicity dosing

Once weekly

Reviewed by Dr. Elena Vance, DOLast reviewed 7 sources cited

Quick Summary

Foundayo (orforglipron) and Trulicity (dulaglutide) are both glp-1 receptor agonist (oral small-molecule)s. In clinical trials, Foundayo showed greater weight loss (12.4% vs 3.1%).

See the comparison table below for detailed side-by-side data.

Foundayo vs Trulicity: Full Comparison

FeatureFoundayo(orforglipron)Trulicity(dulaglutide)
Active Ingredientorforgliprondulaglutide
Drug ClassGLP-1 receptor agonist (oral small-molecule)GLP-1 receptor agonist
ManufacturerEli Lilly and CompanyEli Lilly
FDA Approved2026-04-012014-09-18
Approved Indications
  • Chronic weight management in adults with obesity (BMI >=30 kg/m^2), or overweight (BMI >=27 kg/m^2) with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
Routeoralsubcutaneous injection
FrequencyOnce dailyOnce weekly
Starting Dose3 mg once daily0.75 mg weekly
Maintenance Dose12 mg or 36 mg once daily1.5 mg weekly
Max Dose36 mg once daily4.5 mg weekly
Weight Loss (%)12.4%3.1%
A1C ReductionN/A (not indicated for diabetes)1.5%
Key TrialATTAIN-1 (72 weeks)REWIND (260 weeks)
List PricePricing announced at U.S. launch (April 2026); confirm with LillyDirect$950-$1,100/month
With InsuranceFormulary coverage evolving; many commercial plans expected to require prior authorization$25-$150/month (varies by plan)
Savings CardEli Lilly savings program details emerging via LillyDirect$25/month (Lilly savings card, commercially insured)

Side Effects: Foundayo vs Trulicity

Side EffectFoundayoTrulicity
Nausea21-27%12-21%
Diarrhea15-20%8-13%
Vomiting10-16%6-12%
Constipation8-14%Not reported
Indigestion/dyspepsia6-10%Not reported
Abdominal pain5-9%6-9%
Headache5-8%Not reported
Fatigue4-7%4-6%
Hair loss3-5%Not reported
Pancreatitis (rare)<0.5%<0.5%
Decreased appetiteNot reported4-9%
DyspepsiaNot reported4-6%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Foundayo vs OzempicTrulicity vs OzempicFoundayo vs WegovyTrulicity vs WegovyFoundayo vs MounjaroTrulicity vs MounjaroFoundayo vs ZepboundTrulicity vs Zepbound

Frequently Asked Questions

Sources & References

FDA & Regulatory

  1. Foundayo FDA Drugs@FDA approval record — FDA
  2. Trulicity FDA Drugs@FDA approval record — FDA

Clinical Trial Records

  1. ATTAIN-1 clinical trial record — ClinicalTrials.gov
  2. REWIND clinical trial record — ClinicalTrials.gov

Peer-Reviewed Literature

  1. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet 2019;394:121-130 — The Lancet

Manufacturer Information

  1. Trulicity patient and healthcare provider website — Eli Lilly

Reference Entries

  1. Dulaglutide entry on Wikipedia — Wikipedia

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.